Analyst firms · Barclays · TEVA
Barclays TEVA price target and rating history
Teva Pharmaceutical Industries Limited (TEVA) · Health Care
Barclays rates Teva Pharmaceutical Industries Limited (TEVA) Overweight with a $35 price target, as of its latest action on Dec 9, 2025. It has published 3 rating actions on TEVA since February 2022, including 1 upgrade and 0 downgrades. Across 6 firms with a TEVA price target in the last 12 months, the median target is $47.50. Barclays's $35 is 26% below that.
- Current rating
- Overweight
- Price target
- $35
- Median target, all firms
- $47.50
- Actions on TEVA
- 3
Barclays price target on TEVA
Every Barclays rating on TEVA
- Dec 9, 2025
- Apr 5, 2022
- Feb 18, 2022
How other firms rate TEVA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $52 | Nov 2, 2026 |
| TD Cowen | Buy | $55 | Oct 1, 2026 |
| Oppenheimer | Outperform | $50 | Sep 23, 2026 |
| Leerink Partners | Outperform | $45 | Sep 9, 2026 |
| Barclays | Overweight | $35 | Dec 9, 2025 |
| Scotiabank | Sector Outperform | $35 | Dec 5, 2025 |
Questions about Barclays and TEVA
- What is Barclays's price target for TEVA?
- Barclays's latest stated price target for Teva Pharmaceutical Industries Limited (TEVA) is $35, from its action on Dec 9, 2025.
- What is Barclays's rating on TEVA?
- Barclays rates TEVA Overweight, a bullish rating, as of Dec 9, 2025.
- When did Barclays last change its view on TEVA?
- On Dec 9, 2025, Barclays starts coverage at Overweight, price target $35.
- How does Barclays's TEVA target compare with other analysts?
- Across 6 firms with a TEVA price target in the last 12 months, the median target is $47.50. Barclays's $35 is 26% below that.
More TEVA rating histories
All Barclays ratingsTEVA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.